Medscape
The US Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the treatment of adults with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor. Approval for the new ALK-inhibitor was based on findings from the randomized…
Read More
FDA Approves Ensartinib for ALK+ Advanced NSCLC
Elroy Schildgen
23:23
The US Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the treatment of adults with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor. Approval for the new ALK-inhibitor was based on findings from the randomized…
